Cardiovascular Systems Sponsoring Orbital Atherectomy Sessions at iCON 2013

Cardiovascular Systems Sponsoring Orbital Atherectomy Sessions at iCON 2013

ST. PAUL, Minn. & SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI) (NAS: CSII) , announced today it is sponsoring a challenging case presentation featuring its peripheral orbital atherectomy system, and co-hosting an office-based lab presentation and breakfast session at the International Congress for Endovascular Specialties (iCON) 2013 conference in Scottsdale, Ariz., Feb. 24-28, 2013.

CSI-Sponsored Challenging Case Presentation: Feb. 25

WHAT: Dr. Robert J. Feezor, University of Florida Vascular Surgery, Gainesville, Fla., will present "Challenging Case: Percutaneous Orbital Atherectomy in Lieu of Surgical Reconstruction." Learn how patients with complex and calcified peripheral disease can be treated with a new technology, rather than surgery.

Breakfast Session Co-sponsored by CSI: Feb. 28

WHAT: Dr. Warren Swee, South Florida Vascular Associates, Coconut Creek, Fla., and Dr. Raju Gandhi, Mills-Peninsula Health Services, Burlingame, Calif., will present "Exploring the Future of the Interventional Office Practice" during a breakfast session hosted by CSI, National Cardiovascular Partners and Ziehm Imaging. Learn how physicians are treating patients in this rapidly growing setting.

About Peripheral Arterial Disease
PAD is a life-threatening condition where a fatty material called plaque builds up on the inside walls of the blood vessels that carry blood from the heart to legs and arms. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or personal history of heart disease, heart attack or stroke. PAD affects an estimated 8-12 million people in the United States. The disease prevalence increases with age and 12-20 percent of Americans age 65 and older suffer from PAD symptoms. As the U.S. population ages, the prevalence range could reach 16 million in those age 65 and older and 19 million overall by 2050.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, over 100,000 of CSI's devices have been sold to leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.

For more information, visit the company's website at www.csi360.com.

Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
Sarah Wozniak, 651-259-1636
swozniak@csi360.com
or
Padilla Speer Beardsley Inc.
Matt Sullivan, 612-455-1709
msullivan@padillaspeer.com
or
Dave Folkens, 612-455-1741
dfolkens@padillaspeer.com

KEYWORDS: United States North America Arizona Minnesota

INDUSTRY KEYWORDS:

The article Cardiovascular Systems Sponsoring Orbital Atherectomy Sessions at iCON 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.